4-(3-methoxyphenyl)-1-phenylpiperidine-4-carbonitrile | 106896-79-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3-methoxyphenyl)-1-phenylpiperidine-4-carbonitrile
• 英文别名: 4-cyano-4-(3-methoxyphenyl)-1-phenylpiperidine
• CAS: 106896-79-1
• 化学式: C₁₉H₂₀N₂O
• 分子量: 292.381
• InChiKey: ZXHGZEZNDHZWHT-UHFFFAOYSA-N

物化性质

• 沸点：
  484.8±45.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-methoxyphenyl)-1-phenylpiperidine-4-carbonitrile 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 [1-phenyl-4-(3-methoxyphenyl)piperidin-4-yl]-methylamine
  参考文献：
  名称：

  Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: Dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression

  摘要：

  A family of 1,4-diarylpiperidine-4-methylureas were designed and synthesized as novel dual effectors on ACAT and LDL receptor expression. We examined SAR of the synthesized compounds focusing on substitution at the three aromatic parts of the starting compound 1 and succeeded in identifying essential substituents for inhibition of ACAT and up-regulation of hepatic LDL receptor expression. Especially, we found that compound 12f, which can easily be prepared, has biological properties comparable to those of SMP-797, a promising ACAT inhibitor. In addition, the in vitro effects of 12f on lipid metabolism were substantially superior to those of a known ACAT inhibitor, Avasimibe. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.020
• 作为产物：
  描述：

  N,N-二羟乙基苯胺 在 sodium hydroxide 、 氯化亚砜 、 十六烷基三丁基溴化磷 作用下， 以 氯仿 为溶剂， 反应 2.0h， 生成 4-(3-methoxyphenyl)-1-phenylpiperidine-4-carbonitrile
  参考文献：
  名称：

  凯托米酮前体的合成通过相转移催化

  摘要：

  的盐酸盐ñ -取代的双- （2-氯乙基）胺可以与缩合米甲氧基苯基-乙腈或1-苯基-2-烷酮相转移条件下，以产生强大的镇痛化合物的前体-的ketobemidones。

  DOI：

  10.1002/jhet.5570230115

文献信息

• Novel piperidine derivative
  申请人：Ban Hitoshi

  公开号：US20070078120A1

  公开（公告）日：2007-04-05

  The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0-4, provided 3≦m+n≦8; X is nitrogen atom or a group of the formula: C—R 15 ; Y is a substituted or unsubstituted aromatic group, etc.; R 15 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.

  本发明提供了以下式(1)的化合物：其中m，n和p分别是0-4的整数，满足3≦m+n≦8；X是氮原子或式：C—R15的基团；Y是取代或未取代的芳香基团等；R15，R1，R2，R3，R4，R5，R6和R7是氢原子，取代或未取代的烷基等；Z是氢原子，氰基等，或其前药，或其药学上可接受的盐，具有增强LDL受体表达的作用，并且可用作治疗高脂血症，动脉粥样硬化等药物。
• Novel Sulfonamide derivative
  申请人：Ban Hitoshi

  公开号：US20080096922A1

  公开（公告）日：2008-04-24

  A compound of the formula (1): wherein m, n and p is independently an integer of 0 to 4 with the proviso that 3≦m+n≦8; X is the formula: NR 4 , etc.; R 1 , R 3 and R 4 are a substituted or unsubstituted aryl group, etc.; R 2 is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: —SO 2 —, etc.; and Z is an oxygen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.

  公式（1）的化合物： 其中，m，n和p分别为0至4的整数，但须满足3≦m+n≦8；X为公式：NR4等；R1，R3和R4为取代或未取代的芳基基团等；R2为氢原子等；a，b，c，d，e和f为氢原子或取代或未取代的烷基基团等；Y为公式：—SO2—等；Z为氧原子等；或其前体药物或其药学上可接受的盐具有增强低密度脂蛋白受体表达的活性，因此可用作治疗高脂血症或动脉硬化的药物。
• NOVEL PIPERIDINE DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1679069A1

  公开（公告）日：2006-07-12

  The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0 - 4, provided 3 ≤ m + n ≤ 8; X is nitrogen atom or a group of the formula: C-R15; Y is a substituted or unsubstituted aromatic group, etc.; R15, R1, R2, R3, R4 , R5, R6 and R7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.

  本发明提供了下式（1）的化合物： 其中m、n和p独立地为0-4的整数，条件是3≤m+n≤8；X为氮原子或式中的基团：C-R15；Y 是取代或未取代的芳香基等；R15、R1、R2、R3、R4、R5、R6 和 R7 是氢原子、取代或未取代的烷基等；Z 是氢原子、氰基等、 或其原药或其药学上可接受的盐，具有增强低密度脂蛋白受体表达的作用，可作为治疗高脂血症、动脉粥样硬化等的药物。
• NOVEL SULFONAMIDE DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1736467A1

  公开（公告）日：2006-12-27

  A compound of the formula (1): wherein m, n and p is independently an integer of 0 to 4 with the proviso that 3 ≦ m + n ≦ 8; X is the formula: NR4, etc.; R1, R3 and R4 are a substituted or unsubstituted aryl group, etc.; R2 is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: -SO2-, etc.; and Z is an oxygen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.

  式 (1) 的化合物： 其中 m、n 和 p 独立地为 0 至 4 的整数，但 3 ≦ m + n ≦ 8；X 为式中的NR4等；R1、R3和R4是取代或未取代的芳基等；R2是氢原子等；a、b、c、d、e和f是氢原子或取代或未取代的烷基等；Y是式：-SO2-等：-SO2-等；Z是氧原子等； 或其原药或其药学上可接受的盐具有增强低密度脂蛋白受体表达的活性，因此可用作治疗高脂血症或动脉硬化的药物。
• Synthesis and structure–activity relationships of N-(4-amino-2,6-diisopropylphenyl)-N’-(1,4-diarylpiperidine-4-yl)methylureas as anti-hyperlipidemic agents
  作者：Shigehiro Asano、Hitoshi Ban、Koichi Kino、Katsuhisa Ioriya、Masami Muraoka

  DOI：10.1016/j.bmc.2009.04.059

  日期：2009.7

  Based on 1,4-diarylpiperidine-4-methylureas, a new class of ACAT inhibitors, we examined in the study the SAR of a series of compounds prepared by replacing the substituent at the three aromatic parts. Introduction of long alkoxy group onto the phenyl moiety at the B-part was effective in improving both the inhibitory activity for ACAT and the up-regulatory activity for LDL-R expression. Particularly, 3-hydroxy-propoxy group (43) on the phenyl moiety of B-part led to improved solubility, while keeping both biological activities. Compound 43 inhibited ACAT activity with an IC(50) value of 18 nM, which is superior to that of a known ACAT inhibitor, CI-1011. In addition, compound 43 revealed an LDL-R up-regulatory activity comparable to that of SMP-797. We therefore expect this compound to be a novel ACAT inhibitor. (C) 2009 Elsevier Ltd. All rights reserved.